Plain-English translation of NCT05457283 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether finerenone, a new medication, is safe to use for 18 months in children and young adults ages 1–18 who have chronic kidney disease and protein in their urine. Participants will take this medication in addition to their current blood pressure medication (either an ACE inhibitor or angiotensin receptor blocker). The study wants to make sure the treatment is safe and well-tolerated over a longer period.
Children with chronic kidney disease often don't respond well enough to blood pressure medications alone. This trial exists to see whether adding this medication can help protect the kidneys and reduce protein loss without causing harm over long-term use.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth at home for 18 months, with the dose adjusted based on your age and weight. You would attend study visits where the doctors check your blood pressure, kidney function, and potassium levels, and ask about any side effects. The main goal is to watch how safe and tolerable the medication is over this longer time period.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.